3+ day, 13+ hour ago   (48+ words) HCPLive Antibiotic Pretreatment Improves FMT Response in Peanut Allergy What's Still Missing in IgA Nephropathy Care, With Brad Rovin, MD Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial BEL512 Improves CRSwNP and Symptoms in Phase 2 trial...

3+ day, 14+ hour ago   (461+ words) Rima Rachid, MD, explains how bile acid metabolism and Bacteroides colonization drive durable Treg cell induction after FMT for peanut allergy. RORγt+ regulatory T (Treg) cell expansion following fecal microbiota transplantation (FMT) persisted for up to 12 months in responders with…...

4+ day, 14+ hour ago   (314+ words) Antibiotic pretreatment before oral fecal microbiota transplantation (FMT) raised the peanut allergy response rate to 60% compared with 30% without pretreatment in a phase 1 trial of adults with severe peanut allergy.1,2,3 Omalizumab is now the only FDA-approved option for peanut allergy, following…...

1+ week, 1+ day ago   (249+ words) A Stanford dermatologist explains how AI systems can reinforce racial bias in health care and underperform on skin cancer detection in darker skin. Roxana Daneshjou, MD, PhD, assistant professor of biomedical data science and dermatology at Stanford University, spoke in…...

1+ week, 1+ day ago   (249+ words) HCPLive "Inhaled Antibiotics for Pseudomonas in Bronchiectasis" takes up the decision points that guide inhaled antibiotic use in bronchiectasis patients with pseudomonas Khabbaza how he approaches inhaled antibiotics, particularly for patients whose sputum grows pseudomonas, an organism associated with worse…...

1+ week, 1+ day ago   (236+ words) HCPLive In "Emerging DPP1 Inhibitors and Closing the Education Gap in Bronchiectasis," the panel looks ahead to additional DPP1 inhibitors in development and the gaps still limiting bronchiectasis care Metersky about other DPP1 inhibitors currently in development beyond brensocatib Metersky describes two additional…...

1+ week, 3+ day ago   (348+ words) A JAMA study of nearly 25,000 vitiligo patients reveals major gaps in real-world treatment duration and consistency. Vitiligo remains a chronic condition with limited standardized treatment approaches, and new real-world data are shedding light on just how inconsistent care can be....

1+ week, 5+ day ago   (183+ words) Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin. Continuous glucose monitoring (CGM), initially developed for type 1 diabetes (T1D), has transformed the treatment landscape for type…...

2+ week, 1+ day ago   (351+ words) Despite its high fatality, aortic dissection is a largely underrepresented condition. Genetic history is a clear indicator of disease risk, but due to nationwide issues with autopsy data and a lack of awareness in both patients and clinicians, aortic dissection…...

2+ week, 3+ day ago   (298+ words) Robert Wood, MD, discusses OUTMATCH data showing omalizumab beat multiallergen oral immunotherapy, though MOIT dropouts narrowed the gap. In the intention-to-treat (ITT) population, omalizumab was superior to MOIT for the primary endpoint (36% vs 19%; odds ratio [OR], 2.6; 95% CI, 1.1-6.3; P =.03). This difference…...